Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab
Authors:
Open Access
- 1 November 2022
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (5) , 828-830
Abstract
No abstract availableAll Related Versions
This publication has 8 references indexed in Scilit:
- Management of inadequate response and adverse effects to dupilumab in atopic dermatitisJournal of the American Academy of Dermatology, 2022
- JAK inhibitors in the treatment of atopic dermatitisJournal of Allergy and Clinical Immunology, 2021
- Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapyJAAD Case Reports, 2021
- Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2021
- Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic DermatitisImmunoTargets and Therapy, 2020
- Innovación en dermatitis atópica: de la patogenia a la terapéuticaActas Dermo-Sifiliograficas, 2020
- Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2Journal of Dermatological Treatment, 2019
- JAK/STAT inhibitors for the treatment of atopic dermatitisJournal of Dermatological Treatment, 2019